File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.mce.2014.09.031
- Scopus: eid_2-s2.0-84922345424
- PMID: 25450862
- WOS: WOS:000349880200016
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle
Title | [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle |
---|---|
Authors | |
Keywords | Ghrelin GHSR antagonist Apoptosis Autophagy CXCR4 Skeletal myofibre |
Issue Date | 2015 |
Citation | Molecular and Cellular Endocrinology, 2015, v. 401, p. 155-164 How to Cite? |
Abstract | © 2014 Elsevier Ireland Ltd. [D-Lys3]-GHRP-6 is regarded as a highly selective growth-hormone secretagogue receptor (GHSR) antagonist and has been widely used to investigate the dependency of GHSR-1a signalling mediated by acylated ghrelin. However, [D-Lys3] -GHRP-6 has been reported to influence other cellular processes which are unrelated to GHSR-1a. This study aimed to examine the effects of [D-Lys3]-GHRP-6 on autophagic and apoptotic cellular signalling in skeletal muscle. [D-Lys3] -GHRP-6 enhanced the autophagic signalling demonstrated by the increases in protein abundances of beclin-1 and LC3 II-to-LC3 1 ratio in both normal muscle and doxorubicin-injured muscle. [D-Lys3]-GHRP-6 reduced the activation of muscle apoptosis induced by doxorubicin. No histological abnormalities were observed in the [D-Lys3] -GHRP-6-treated muscle. Intriguingly, the doxorubicin-induced increase in centronucleated muscle fibres was not observed in muscle treated with [D-Lys3]-GHRP-6, suggesting the myoprotective effects of [D-Lys3] -GHRP-6 against doxorubicin injury. The [D-Lys3]-GHRP-6-induced activation of autophagy was found to be abolished by the co-treatment of CXCR4 antagonist, suggesting that the pro-autophagic effects of [D-Lys3] -GHRP-6 might be mediated through CXCR4. In conclusion, [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle under both normal and doxorubicin-injured conditions. |
Persistent Identifier | http://hdl.handle.net/10722/244186 |
ISSN | 2021 Impact Factor: 4.369 2020 SCImago Journal Rankings: 1.296 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, Angus P. | - |
dc.contributor.author | Pei, Xiao M. | - |
dc.contributor.author | Sin, Thomas K. | - |
dc.contributor.author | Yip, Shea P. | - |
dc.contributor.author | Yung, Benjamin Y. | - |
dc.contributor.author | Chan, Lawrence W. | - |
dc.contributor.author | Wong, Cesar S. | - |
dc.contributor.author | Siu, Parco M. | - |
dc.date.accessioned | 2017-08-31T08:56:17Z | - |
dc.date.available | 2017-08-31T08:56:17Z | - |
dc.date.issued | 2015 | - |
dc.identifier.citation | Molecular and Cellular Endocrinology, 2015, v. 401, p. 155-164 | - |
dc.identifier.issn | 0303-7207 | - |
dc.identifier.uri | http://hdl.handle.net/10722/244186 | - |
dc.description.abstract | © 2014 Elsevier Ireland Ltd. [D-Lys3]-GHRP-6 is regarded as a highly selective growth-hormone secretagogue receptor (GHSR) antagonist and has been widely used to investigate the dependency of GHSR-1a signalling mediated by acylated ghrelin. However, [D-Lys3] -GHRP-6 has been reported to influence other cellular processes which are unrelated to GHSR-1a. This study aimed to examine the effects of [D-Lys3]-GHRP-6 on autophagic and apoptotic cellular signalling in skeletal muscle. [D-Lys3] -GHRP-6 enhanced the autophagic signalling demonstrated by the increases in protein abundances of beclin-1 and LC3 II-to-LC3 1 ratio in both normal muscle and doxorubicin-injured muscle. [D-Lys3]-GHRP-6 reduced the activation of muscle apoptosis induced by doxorubicin. No histological abnormalities were observed in the [D-Lys3] -GHRP-6-treated muscle. Intriguingly, the doxorubicin-induced increase in centronucleated muscle fibres was not observed in muscle treated with [D-Lys3]-GHRP-6, suggesting the myoprotective effects of [D-Lys3] -GHRP-6 against doxorubicin injury. The [D-Lys3]-GHRP-6-induced activation of autophagy was found to be abolished by the co-treatment of CXCR4 antagonist, suggesting that the pro-autophagic effects of [D-Lys3] -GHRP-6 might be mediated through CXCR4. In conclusion, [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle under both normal and doxorubicin-injured conditions. | - |
dc.language | eng | - |
dc.relation.ispartof | Molecular and Cellular Endocrinology | - |
dc.subject | Ghrelin | - |
dc.subject | GHSR antagonist | - |
dc.subject | Apoptosis | - |
dc.subject | Autophagy | - |
dc.subject | CXCR4 | - |
dc.subject | Skeletal myofibre | - |
dc.title | [D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.mce.2014.09.031 | - |
dc.identifier.pmid | 25450862 | - |
dc.identifier.scopus | eid_2-s2.0-84922345424 | - |
dc.identifier.volume | 401 | - |
dc.identifier.spage | 155 | - |
dc.identifier.epage | 164 | - |
dc.identifier.eissn | 1872-8057 | - |
dc.identifier.isi | WOS:000349880200016 | - |
dc.identifier.issnl | 0303-7207 | - |